News Agency News Aggregator Journalist/Editor Broking House Others
#SharekhanFNA #SharekhanResearch #Q2FY21 expected to be healthy qtr for pharma cos; Exports to largely drive the performance; sales to grow 7.6% yoy while PAT to grow 14.5% Prefer#Aurobindo#Cipla#DivisLab#LaurusLab#Granules#SanofiIndi#AbbottIndia#StridesPharma#ShilpaMedicare
Today's #Infographic: The Fat Dividend Paying Pharma Companies by @DhanValue Includes: 1. Pfizer 2. Sanofi 3. Abbott India 4. Torrent Pharma 5. Alembic Pharma 6. Piramal Enterprises
Trading Tweaks 💫AGM Date: Abbott India, Aditya Birla Fashion Retail, Indiabulls Housing Finance, NACL (cont) https://t.co/9RogPXyxpf
Trading Tweaks 🔆AGM Date: Ashok Leyland, Ramco Industries, Ramco Systems, Abbott India, Fermenta Biotech. (cont) https://t.co/dz4UiN4mwZ
ABBOTT INDIA In Focus Can be Negative for Thyrocare, Dr lal
Reading Icici sec sees margins improving by 470 bp for Abbott india over next 2 years driven by branded business, focus on digital mktg, operating leverage in core portfolio. Coupled with healthy earning growth, free cash flows of 1800 cr could flow over this period.
#SharekhanFNA #SharekhanResearch retains Neutral view on #Pharmaceutical sector Q1FY21 was strong quarter for Pharma cos; though valuations seem reasonable for most cos US bizz likely to be under stress; preferred picks #Divislabs#LaurusLabs #Granules #SanofiIndia #Abbott India
CLSA On Abbott India Buy rating maintained Price target of Rs 20,000 For daily Buy/Sell calls, Subscribe here:
#BrokerageRadar: CLSA on Abbott India
#CNBCTV18Market | CLSA reiterates BUY call on Abbott India, sets target at Rs 20,000/sh
Abbott India - Strong performance despite challenges - ICICI Securities #AbbottIndia @ICICI_Direct #ICICISecurities
#SharekhanFNA #SharekhanResearch retains Positive view on #AbbottIndia (upside 18-20%); strong results for Q1FY21; power brands have leadership position in their respective segment & growth traction to sustain; better earning visibility strong balance sheet & cashflow augur well
#Abbott India: The company reported a 54.22% rise in its net profit to ₹180.35 crore for the quarter to June 2020. Abbott India had posted a net profit of ₹116.94 crore for the corresponding period of the previous fiscal.